Orange Book Blog

At the intersection of Patent and FDA Law

Recent Posts

Month: February 2007

  • Amphastar and Teva Prevail Over Aventis in Generic Lovenox Trial, But Still May Not Receive FDA Approval

    Aventis Pharma v. Amphastar Pharms., No. 03-887 (C.D. Cal. 2007) In a ruling issued last Friday, Judge Mariana R. Pfaelzer of the U.S. District Court for the Central District of California held Aventis’s U.S. Patent No. 5,389,618 and its U.S. Reissue Patent No. 38,743 unenforceable due to inequitable conduct.  The patents cover Lovenox (enoxaparin), a…

  • IQPC “Pharmaceutical & Biotech Patent Litigation Strategies 2007” Conference, March 27-28, London

    International Quality & Productivity Center has announced that its "Pharmaceutical & Biotech Patent Litigation Strategies 2007" conference will be held March 27-28, 2007, in London, England.  The conference will cover the evolving trends in both Europe and the United States.  Speakers include in-house counsel from major pharmaceutical companies as well as outside counsel who specialize…

  • FTC Pursues Antitrust Case Against Barr Labs After District Court Denies Barr’s Motion to Dismiss

    Federal Trade Comm’n v. Warner Chilcott Holdings, No. 05-2179 (D. D.C. 2007) Judge Colleen Kollar-Kotelly of the U.S. District Court for the District of Columbia recently denied Barr Laboratories’ motion to dismiss a Federal Trade Commission lawsuit stemming from Barr’s agreement with Warner Chilcott concerning generic Ovcon 35.  The opinion is available here. In 2001,…

  • ACI “FDA Boot Camp” Conference, March 26-27, NYC

    American Conference Institute has announced that its third FDA Boot Camp will be taking place March 26-27, 2007, in New York, New York.  According to ACI, the inaugural FDA Boot Camp conference, held in New York last March, was sold out, as was this past September’s FDA Boot Camp in Chicago.  Designed for product liability…

  • Pharma News Briefs

    The Antitrust & Competition Policy Blog reports on a new paper by Prof. Christopher Leslie of Chicago-Kent College of Law advocating the use of antitrust law to challenge the licensing of invalid patents. Richard Epstein, my law school Property professor, has a new book out entitled Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation.  Judy…

  • Pfizer Wins Another Round in Norvasc Case as Synthon’s Patents Are Found Unenforceable

    Synthon IP v. Pfizer, No. 05-1267 (E.D. Va. 2007) As we previously reported, last year a jury in the Eastern District of Virginia found that Pfizer does not infringe Synthon IP, Inc.'s patent on processes for making the active ingredient in Norvasc (amlodipine besylate) and also that the patent is invalid.  Now, following a bench…

  • Senators Reintroduce Bill to Ban Authorized Generics

    Senator Jay Rockefeller (D-WV) has introduced S. 438, "The Fair Prescription Drug Act of 2007," which would ban the sale of authorized generic drugs during an ANDA applicant’s 180-day exclusivity period.  The bill is cosponsored by Senators Kohl (D-WI), Leahy, (D-VT), and Schumer (D-NY).  The same bill was proposed last year as S. 3695.  Senator…